On the other hand, the results of other studies suggest that IL17/A production may also empower the cytotoxic activity of pre-existing effector CTLs in the tumor site [28].This finding could also partially explain the predictive value of IL17/A baseline levels only in patients with k-ras/mut and in patients who receive TSPP vaccination and GOLFIG chemo-immunotherapy (Arm-C/DL0-3). The gene discussed is IL17A; the disease is neoplasm.